Stockreport

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial [CNBC]

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview
PDF The treatment uses Nobel Prize-winning Crispr technology to edit DNA and treat hereditary angioedema, a condition that causes potentially life-threatening swelling atta [Read more]